Increased 68 Ga-FAPI Uptake in Dermatofibrosarcoma Protuberans

Fibroblast Activation Protein Inhibitor (FAPI)-PET Imaging in Sarcoma

Advances in histopathologic and molecular genetic subtyping of sarcoma will potentially allow identification of novel diagnostic and therapeutic targets for specific subtypes, but a "pan-sarcoma" target is needed. This article provides an overview on expression of one potential candidate, fibroblast activation protein alpha in soft tissue and bone sarcoma, and the resulting application of 68Ga-FAPI as novel imaging probes in these rare tumor entities. Current preclinical and clinical data on 68Ga-FAPI-PET/CT in sarcomas are summarized. 68Ga-FAPI-PET-CT potentially offers important complementary information to be used in diagnostic work-up, assessment of therapy response, and prognostication of soft tissue and bone sarcomas.

Mesenteric Mesonephric Adenocarcinoma on 68 Ga-FAPI PET/CT

ABSTRACT

Mesenteric mesonephric adenocarcinoma is an uncommon mesenteric neoplasm, which was arising from the mesonephric remnant of the female reproductive tract. Herein, we report the 68 Ga-FAPI PET/CT findings in a 66-year-old woman with mesenteric mesonephric adenocarcinoma.